Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
An update from Carmell Therapeutics (CTCX) is now available.
Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepping down as CEO, to be succeeded by Kendra Bracken-Ferguson, effective July 30, 2024. Bracken-Ferguson, a seasoned professional in the digital media and beauty industries, will bring her extensive experience from founding BrainTrust and developing over 200 influencer-driven brands to her new role. Alongside a base salary of $300,000, her compensation includes performance-based bonuses and equity awards, with additional severance benefits outlined in her executive employment agreement.
See more data about CTCX stock on TipRanks’ Stock Analysis page.
